Liao BC - Search Results

1

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.

Wu SG, Ho CC, Yang JC, Yu SH, Lin YF, Lin SC, Liao BC, Yang CY, Lin YT, Yu CJ, Chuang YT, Liao WY, Yap KY, Kou WS, Shih JY. Wu SG, et al. Among authors: liao bc. Clin Transl Med. 2025 Jan;15(1):e70149. doi: 10.1002/ctm2.70149. Clin Transl Med. 2025. PMID: 39715697 Free PMC article. Clinical Trial.

2

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.

Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Liao BC, et al. J Thorac Oncol. 2015 Dec;10(12):1754-61. doi: 10.1097/JTO.0000000000000669. J Thorac Oncol. 2015. PMID: 26334749 Free article.

3

Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Huang DD, Liao BC, Hsu WH, Yang CY, Lin YT, Wu SG, Tsai TH, Chen KY, Ho CC, Liao WY, Shih JY, Yu CJ, Yang JC, Cheng AL, Shen YC. Huang DD, et al. Among authors: liao bc. Oncology. 2024;102(4):318-326. doi: 10.1159/000534350. Epub 2023 Sep 29. Oncology. 2024. PMID: 37778345 Free article.

4

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Liao BC, Bai YY, Lee JH, Lin CC, Lin SY, Lee YF, Ho CC, Shih JY, Chang YC, Yu CJ, Chih-Hsin Yang J, Yang PC. Liao BC, et al. J Formos Med Assoc. 2018 Apr;117(4):326-331. doi: 10.1016/j.jfma.2017.04.018. Epub 2017 May 9. J Formos Med Assoc. 2018. PMID: 28499641 Free article.

5

First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Drugs. 2013 Mar;73(4):357-69. doi: 10.1007/s40265-013-0020-8. Drugs. 2013. PMID: 23479407 Review.

6

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Curr Opin Oncol. 2015 Mar;27(2):94-101. doi: 10.1097/CCO.0000000000000164. Curr Opin Oncol. 2015. PMID: 25611025 Review.

7

Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study.

Liao BC, Yang JC. Liao BC, et al. Transl Lung Cancer Res. 2012 Sep;1(3):227-9. doi: 10.3978/j.issn.2218-6751.2012.09.05. Transl Lung Cancer Res. 2012. PMID: 25806186 Free PMC article. No abstract available.

8

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Liao BC, Lin CC, Shih JY, Yang JC. Liao BC, et al. Ther Adv Med Oncol. 2015 Sep;7(5):274-90. doi: 10.1177/1758834015590593. Ther Adv Med Oncol. 2015. PMID: 26327925 Free PMC article. Review.

9

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

Liao BC, Lin CC, Lee JH, Yang JC. Liao BC, et al. J Biomed Sci. 2016 Dec 3;23(1):86. doi: 10.1186/s12929-016-0305-9. J Biomed Sci. 2016. PMID: 27912760 Free PMC article. Review.

10

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.

Liao BC, Lin CC, Yang JC. Liao BC, et al. Curr Oncol Rep. 2017 Jan;19(1):4. doi: 10.1007/s11912-017-0560-2. Curr Oncol Rep. 2017. PMID: 28138934 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters